VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation.
Tumors initiate angiogenesis primarily by secreting vascular endothelial growth factor (VEGF-A(164)). The first new vessels to form are greatly enlarged, pericyte-poor sinusoids, called mother vessels (MV), that originate from preexisting venules. We postulated that the venular enlargement necessary to form MV would require a selective degradation of their basement membranes, rigid structures that resist vascular expansion. To identify the specific proteases responsible for MV formation, we induced angiogenesis in mouse tissues with an adenoviral vector expressing VEGF-A(164) (Ad-VEGF-A(164)) or with VEGF-A-secreting TA3/St mammary tumors. We found that MV formation resulted from greatly increased activity of cathepsins (B>S>L) in venules transitioning into MV, as well as from a reciprocal decrease in the expression of several cysteine protease inhibitors (CPI), stefin A and cystatins B and C, by these same venules. Using a fluorescence probe that selectively binds cellular sites of cathepsin protease activity in vivo, we showed that increased cathepsin activity was localized exclusively to perivenular cells, not to venule endothelial cells. CPI strikingly inhibited angiogenesis in the Matrigel assay, and Ad-VEGF-A(164)-induced angiogenesis was reduced by approximately 50% in cathepsin B-null mice. Thus, VEGF-A, whether expressed by interstitial cells infected with an adenoviral vector or by tumor cells, upsets the normal cathepsin-CPI balance in nearby venules, leading to degradation of their basement membranes, an important first step in angiogenesis.
Chang
Sung-Hee
SH
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Kanasaki
Keizo
K
Gocheva
Vasilena
V
Blum
Galia
G
Harper
Jay
J
Moses
Marsha A
MA
Shih
Shou-Ching
SC
Nagy
Janice A
JA
Joyce
Johanna
J
Bogyo
Matthew
M
Kalluri
Raghu
R
Dvorak
Harold F
HF
D000818:Animals; D002403:Cathepsins / Q000037:antagonists & inhibitors / Q000235:genetics*; D055312:Cystatin A / Q000235:genetics / Q000494:pharmacology; D055313:Cystatin B / Q000172:deficiency / Q000494:pharmacology; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D051379:Mice; D018345:Mice, Knockout; D008819:Mice, Nude; D008833:Microcirculation / Q000187:drug effects / Q000502:physiology; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000503:physiopathology*; D016133:Polymerase Chain Reaction; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology*; D014699:Venules / Q000187:drug effects / Q000502:physiology*
D055312:Cystatin A; D015853:Cysteine Proteinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; D055313:Cystatin B; D002403:Cathepsins